This is the presentation I had at the CCIF meeting at Guiyang, China, April 2015.
Which is the current role of Bivalirudin in ACS patients, nowadays? Did the Matrix trial change the scenario, or created more confusion on the matter?
Posted on by Bernardo Cortese
Posted in Current research on Antithrombotics, Faculty at Medical Meetings, since 2010, Upcoming Scientific Meetings
Leave a comment
Bivalirudin use-an update after the Matrix trial
Leave a comment Cancel reply
You must be logged in to post a comment.